{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T14:05:12Z","timestamp":1771337112160,"version":"3.50.1"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T00:00:00Z","timestamp":1685318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Fondaparinux is a synthetic anticoagulant for the prevention of venous thromboembolism (VTE), and its administration in Chinese cancer patients is rarely reported. This study aimed to assess the efficacy and safety of fondaparinux in preventing VTE in Chinese cancer patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 224 cancer patients who received fondaparinux treatment were reviewed in this single-arm, multicenter, retrospective study. Meanwhile, VTE, bleeding, death, and adverse events of those patients in the hospital and at 1 month after treatment (M1) were retrieved, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The in-hospital VTE rate was 0.45% and there was no (0.00%) VTE occurrence at M1. The in-hospital bleeding rate was 2.68%, among which the major bleeding rate was 2.23% and the minor bleeding rate was 0.45%. Moreover, the bleeding rate at M1 was 0.90%, among which both the major and minor bleeding rates were 0.45%. The in-hospital death rate was 0.45% and the death rate at M1 was 0.90%. Furthermore, the total rate of adverse events was 14.73%, including nausea and vomiting (3.13%), gastrointestinal reactions (2.23%), and reduced white blood cells (1.34%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Fondaparinux could effectively prevent VTE with low bleeding risk and acceptable tolerance in cancer patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1165437","type":"journal-article","created":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T04:16:24Z","timestamp":1685333784000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of fondaparinux in preventing venous thromboembolism in Chinese cancer patients: a single-arm, multicenter, retrospective study"],"prefix":"10.3389","volume":"13","author":[{"given":"Lei","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhong","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunying","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruijun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2165\/1158583-S0-000000000-00000","article-title":"Overview of venous thromboembolism","volume":"70","author":"Abad Rico","year":"2010","journal-title":"Drugs"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13570","article-title":"Approach to cancer-associated thrombosis: challenging situations and knowledge gaps","volume":"26","author":"Wang","year":"2021","journal-title":"Oncologist"},{"key":"B3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.beha.2008.12.001","article-title":"Epidemiology of cancer-related venous thromboembolism","volume":"22","author":"Wun","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.2.190","article-title":"Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon","volume":"164","author":"Otten","year":"2004","journal-title":"Arch Intern Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-020-02180-x","article-title":"Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE","volume":"50","author":"Weitz","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005819","article-title":"Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis","volume":"136","author":"Mulder","year":"2020","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(20)30402-3","article-title":"Clinical practice guidelines for the treatment and prevention of cancer-associated thrombosis","volume":"191","author":"Lyman","year":"2020","journal-title":"Thromb Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2020.1711731","article-title":"A comprehensive evaluation of apixaban in the treatment of venous thromboembolism","volume":"13","author":"Koehl","year":"2020","journal-title":"Expert Rev Hematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-021-06598-8","article-title":"Incidence, risk factors, and management of bleeding in patients receiving anticoagulants for the treatment of cancer-associated thrombosis","volume":"30","author":"Frere","year":"2022","journal-title":"Support Care Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01345-5","article-title":"Prevention and treatment of bleeding with direct oral anticoagulants","volume":"80","author":"Crawley","year":"2020","journal-title":"Drugs"},{"key":"B11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/bs.pmbts.2019.02.004","article-title":"The clinical use of fondaparinux: a synthetic heparin pentasaccharide","volume":"163","author":"Zhang","year":"2019","journal-title":"Prog Mol Biol Transl Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2002.38.3.820126","article-title":"Fondaparinux sodium","volume":"38","author":"Reverter","year":"2002","journal-title":"Drugs Today (Barc)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"101354","DOI":"10.1016\/j.beha.2022.101354","article-title":"Treatment modalities in cancer-associated venous thromboembolism (VTE)","volume":"35","author":"Soto Alsar","year":"2022","journal-title":"Best Pract Res Clin Haematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S106153","article-title":"Fondaparinux vs warfarin for the treatment of unsuspected pulmonary embolism in cancer patients","volume":"10","author":"Amato","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp120711","article-title":"Comparison of injectable anticoagulants for thromboprophylaxis after cancer-related surgery","volume":"71","author":"Changolkar","year":"2014","journal-title":"Am J Health Syst Pharm"},{"key":"B16","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(20)32658-1","article-title":"Venous thromboembolism","volume":"398","author":"Khan","year":"2021","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jjcc.2021.08.026","article-title":"Venous thromboembolism: recent advancement and future perspective","volume":"79","author":"Yamashita","year":"2022","journal-title":"J Cardiol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0207410","article-title":"A systematic review of clinical practice guidelines on the use of low molecular weight heparin and fondaparinux for the treatment and prevention of venous thromboembolism: implications for research and policy decision-making","volume":"13","author":"Johnston","year":"2018","journal-title":"PloS One"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2017.04.014","article-title":"Efficacy and safety of thromboembolism prophylaxis with fondaparinux in Japanese colorectal cancer patients undergoing laparoscopic surgery: a phase II study","volume":"42","author":"Tokuhara","year":"2017","journal-title":"Int J Surg"},{"key":"B20","doi-asserted-by":"publisher","first-page":"114256","DOI":"10.1016\/j.ejmech.2022.114256","article-title":"Chemical synthesis and pharmacological properties of heparin pentasaccharide analogues","volume":"234","author":"Zhou","year":"2022","journal-title":"Eur J Med Chem"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011099","article-title":"Steering committee of the pentasaccharide in major knee surgery s. fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery","volume":"345","author":"Bauer","year":"2001","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1586\/14737167.7.3.227","article-title":"Fondaparinux sodium in the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism","volume":"7","author":"Wade","year":"2007","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/58.suppl_2.S14","article-title":"Fondaparinux sodium: a selective inhibitor of factor xa","volume":"58","author":"Bauer","year":"2001","journal-title":"Am J Health Syst Pharm"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.4.458","article-title":"Incidence of venous thromboembolism and its effect on survival among patients with common cancers","volume":"166","author":"Chew","year":"2006","journal-title":"Arch Intern Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ijcard.2019.06.032","article-title":"The association of recurrence and bleeding events with mortality after venous thromboembolism: from the COMMAND VTE registry","volume":"292","author":"Yamashita","year":"2019","journal-title":"Int J Cardiol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2147\/JBM.S285214","article-title":"Antithrombotic and anti-inflammatory effects of fondaparinux and enoxaparin in hospitalized COVID-19 patients: the FONDENOXAVID study","volume":"12","author":"Cardillo","year":"2021","journal-title":"J Blood Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14642","article-title":"Fondaparinux pentasaccharide reduces sepsis coagulopathy and promotes survival in the baboon model of escherichia coli sepsis","volume":"18","author":"Keshari","year":"2020","journal-title":"J Thromb Haemost"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1165437\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T04:16:27Z","timestamp":1685333787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1165437\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,29]]},"references-count":27,"alternative-id":["10.3389\/fonc.2023.1165437"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1165437","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,29]]},"article-number":"1165437"}}